ArticleMolecular therapy : the journal of the American Society of Gene Therapy2023
PARP1 modulates METTL3 promoter chromatin accessibility and associated LPAR5 RNA m
Open access · greenAbstract read
In one paragraph
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Inhibiting METTL3 synergizes with Notch blockade to treat ESCC by targeting cancer stemness via m6A-JAG2.Journal of gastroenterology · 2026Article
- The Role of NMedComm · 2026Review
- METTL3 in esophageal cancer: Current insights into molecular mechanisms, subtype heterogeneity and targeted therapy prospects (Review).International journal of oncology · 2026Review
- mCell death and differentiation · 2026Article
- Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders.Biomolecules · 2026Review
- Targeting mDiscover oncology · 2026Review
- Dynamic modulation of N6-methyladenosine by ionizing radiation in human cells.Biochemistry and biophysics reports · 2026Article
- Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions.MedComm · 2026Review
- Multi-omics reveals that genes linked to succinylation regulate the onset of epilepsy through metabolic reprogramming.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- CCNE1 Exerts a Protective Effect on Parkinson's Disease by Regulating Ferroptosis-Related Proteins.Brain and behavior · 2025Article
- PARP1 contributes to intimal hyperplasia by regulating METTL3-mediated m6A methylation of TRAIL.Cell biology and toxicology · 2025Article
- The crosstalk of mTrends in biochemical sciences · 2025Review
- The dual mechanism of mCell death & disease · 2025Article
- Lactylation: From Homeostasis to Pathological Implications and Therapeutic Strategies.MedComm · 2025Review
- Molecular mechanisms of m6A modifications regulating tumor radioresistance.Molecular medicine (Cambridge, Mass.) · 2025Review
- The interplay between RNA m6A modification and radiation biology of cancerous and non-cancerous tissues: a narrative review.Cancer biology & medicine · 2025Review
- Advances in research on RNA methylation and cancer radiotherapy resistance.Frontiers in oncology · 2025Review
- Case Report: Clinical and molecular features of a radiosensitive autoimmune polyendocrine syndrome type 1 patient with oral carcinoma.Frontiers in genetics · 2025Article
- METTL3-mediated m6A modification of SLC7A11 enhances nasopharyngeal carcinoma radioresistance by inhibiting ferroptosis.International journal of biological sciences · 2025Article
- YY1 drives PARP1 expression essential for PARylation of NONO in mRNA maturation during neuroblastoma progression.Journal of translational medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Xiaoya SunSchool of Public Health, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China; Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China.
Chenjun BaiDepartment of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China.
Haozheng LiSchool of Public Health, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China; Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China.
Dafei XieDepartment of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China.
Shi ChenSchool of Public Health, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China; Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China.
Yang HanDepartment of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China.
Jinhua LuoDepartment of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China; Department of Occupational and Environmental Health, Xiangya School of Public Health, Central South University, Changsha, Hunan 410078, P.R. China.
Yang LiDepartment of Experimental Pathology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China.
Yumeng YeDepartment of Experimental Pathology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China.
Jin JiaSchool of Public Health, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China; Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China.
Xin HuangDepartment of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China.
Hua GuanDepartment of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China.
Dingxin LongSchool of Public Health, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China.
Ruixue HuangDepartment of Occupational and Environmental Health, Xiangya School of Public Health, Central South University, Changsha, Hunan 410078, P.R. China. Electronic address: huangruixue@csu.edu.cn.
Shanshan GaoDepartment of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China. Electronic address: gaoshanbprc@163.com.
Ping-Kun ZhouSchool of Public Health, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China; Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China. Electronic address: zhoupk@bmi.ac.cn.
Beijing Radiation Center · CNUniversity of South China · CNCentral South University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromatin remodeling and N
Indexed as
ChromatinNeoplasmsAnimalsHumansMethylationMethyltransferasesMicePoly (ADP-Ribose) Polymerase-1Receptors, Lysophosphatidic AcidRNARNA, MessengerTranscription FactorsChromatinLPAR5 protein, humanMethyltransferasesMETTL3 protein, humanPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Receptors, Lysophosphatidic AcidRNARNA, MessengerTranscription Factorschromatin accessibilityDNA damage responsem(6)A methylationPARP1radiosensitivity
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.